Neurocrine Biosciences ((NBIX)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurocrine Biosciences is conducting a Phase 2 study titled A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization. The study aims to evaluate the efficacy, safety, and pharmacokinetics of NBI-1117568, a drug intended to treat adults with schizophrenia experiencing acute symptom exacerbations.
The intervention being tested is NBI-1117568, an orally administered drug, compared against a placebo. The study includes multiple experimental groups receiving different dose levels of the drug over six weeks.
This interventional study employs a randomized, parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are unaware of group assignments. The primary purpose of the study is treatment-focused.
The study began on October 4, 2022, with its primary completion and last update submitted on July 9, 2025. These dates are crucial as they mark the progress and data availability for further analysis and review.
The completion of this study could significantly impact Neurocrine Biosciences’ stock performance, as successful results may enhance investor confidence and market position. It is important to consider the competitive landscape, as advancements in schizophrenia treatment can influence industry dynamics.
The study is completed, with further details available on the ClinicalTrials portal.